Atlas.
Sign inStart free trial
DNLINASDAQ · US

Denali Therapeutics Inc.

Technology · Biological Products, (No Diagnostic Substances)

TechnologyBiological Products, (No Diagnostic Substances)
CEO
Ryan Watts, Ph.D.
Founded
—
IPO Date
—
HQ
South San Francisco, CA, United States
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$25.98 ▲ 59.7%
Last (1 Jul 2026) · $26
Period High · $25.98
Period Low · $0.00
52W: $25.98 – $25.98

Key Metrics

Share Price
$25.98
+1.0% today
Market Cap
$3.8B
P / E
—
EV / Revenue
—
Revenue Growth
—
year-on-year
Gross Margin
—
Enterprise Value
$3.6B
52W High
$25.98
52W Low
$0.00
Avg Volume
1.8M
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
13 known institutional holders·$774M total on record·2026-Q1
BlackRock, Inc.
8.9%·$250M
State Street Corp
4.3%·$120M
Fmr LLC
3.1%·$88M
Goldman Sachs Group Inc
3.0%·$85M
Geode Capital Management, LLC
2.5%·$72M
Dimensional Fund Advisors LP
1.8%·$52M
Capital Research Global Investors
1.7%·$48M
Price T Rowe Associates Inc
1.7%·$47,313
Northern Trust Corp
0.9%·$25M
Bank Of America Corp
0.8%·$22M
Jpmorgan Chase & Co
0.2%·$6M
Invesco Ltd.
0.2%·$6M
Point72 Asset Management, L.P.
0.0%·$867,840
Free Float
70.8%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for Denali Therapeutics Inc.
OverviewDenali Therapeutics Inc. share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow Denali Therapeutics Inc. generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsDenali Therapeutics Inc.'s complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityDenali Therapeutics Inc. executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsDenali Therapeutics Inc.'s annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for Denali Therapeutics Inc., updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for Denali Therapeutics Inc. aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersDenali Therapeutics Inc. valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for Denali Therapeutics Inc. with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for Denali Therapeutics Inc. — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial